MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Search

Glaukos Corp

Closed

SectorHealthcare

87.08 2.29

Overview

Share price change

24h

Current

Min

87.08

Max

88.86

Key metrics

By Trading Economics

Income

-1.5M

-20M

Sales

17M

124M

Profit margin

-15.837

Employees

995

EBITDA

12M

-8.6M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+32.3% upside

Dividends

By Dow Jones

Next Earnings

30 paź 2025

Market Stats

By TradingEconomics

Market Cap

-659M

4.8B

Previous open

84.79

Previous close

87.08

News Sentiment

By Acuity

43%

57%

123 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Glaukos Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

19 paź 2025, 20:00 UTC

Acquisitions, Mergers, Takeovers

Infratil Agrees to NZ$437.7 Million Deal to Raise Contact Energy Stake

19 paź 2025, 23:44 UTC

Market Talk

Gold Edges Lower Amid Signs of U.S.-China Trade Tensions Easing -- Market Talk

19 paź 2025, 23:37 UTC

Market Talk

New Zealand's Core CPI Keeps Rate Cut Hopes Alive -- Market Talk

19 paź 2025, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street Gains -- Market Talk

19 paź 2025, 23:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19 paź 2025, 23:09 UTC

Market Talk

Could Rio Tinto, BHP Ally to Defend Iron-Ore Pricing Power? -- Market Talk

19 paź 2025, 22:41 UTC

Acquisitions, Mergers, Takeovers

Luxury Fashion House Kering Confirms Beauty Deal With L'Oréal -- Barrons.com

19 paź 2025, 22:30 UTC

Earnings

Stock Futures Rise Ahead of Major Week of Earnings -- Barrons.com

19 paź 2025, 22:18 UTC

Market Talk

Gold at $5,000 on Cards as Investors Get Comfortable -- Market Talk

19 paź 2025, 21:50 UTC

Market Talk

Infratil's Contact Stake Buy May Require Bigger Asset Sales -- Market Talk

19 paź 2025, 21:15 UTC

Market Talk

Investors Need to Change Narrative Toward Scales -- Market Talk

19 paź 2025, 19:34 UTC

Acquisitions, Mergers, Takeovers

Infratil's Contact Shareholding to Rise to 14.3% When Deal Completes

19 paź 2025, 19:34 UTC

Acquisitions, Mergers, Takeovers

Infratil to Issue New Shares Worth NZ$218.8 Million to TECT at NZ$12.43 Each

19 paź 2025, 19:33 UTC

Acquisitions, Mergers, Takeovers

Infratil Part-Funding Purchase of Contact Energy Stake With NZ$218.8 Million of Existing Debt

19 paź 2025, 19:32 UTC

Acquisitions, Mergers, Takeovers

Infratil Acquiring Additional Contact Energy Stake for NZ$8.95/Share

19 paź 2025, 19:32 UTC

Acquisitions, Mergers, Takeovers

Infratil Acquiring Contact Energy Stake for NZ$437.7 Million

19 paź 2025, 19:31 UTC

Acquisitions, Mergers, Takeovers

Infratil Acquiring TECT Holdings's Shareholding in Contact Energy

19 paź 2025, 19:31 UTC

Acquisitions, Mergers, Takeovers

Infratil to Acquire Additional 4.92% Stake in Contact Energy

19 paź 2025, 16:29 UTC

Earnings

Elon Musk Pay Drama Heats Up Ahead of Tesla Earnings -- Barrons.com

19 paź 2025, 11:14 UTC

Earnings

Zijin Mining 3Q Oper Income CNY86.49B; up 8.1% on Year>2899.HK

19 paź 2025, 11:14 UTC

Earnings

Zijin Mining: Higher Sales of Gold, Copper Supported Results >2899.HK

19 paź 2025, 11:14 UTC

Earnings

Zijin Mining 3Q Net CNY14.57B; up 57.1% on Year>2899.HK

18 paź 2025, 13:30 UTC

Acquisitions, Mergers, Takeovers

Deal Expected to Value Unit at Roughly $4B, Sources Say -- WSJ

18 paź 2025, 13:30 UTC

Acquisitions, Mergers, Takeovers

Deal Could Be Announced as Soon as Next Week, Sources Say -- WSJ

18 paź 2025, 13:30 UTC

Acquisitions, Mergers, Takeovers

Gucci Owner Kering Nears $4 Billion Sale of Beauty Unit to L'Oréal -- WSJ

18 paź 2025, 13:30 UTC

Acquisitions, Mergers, Takeovers

Gucci Parent Kering in Talks to Sell Beauty Business to L'Oréal, Sources Say -- WSJ

18 paź 2025, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

17 paź 2025, 23:25 UTC

Acquisitions, Mergers, Takeovers

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17 paź 2025, 22:15 UTC

Market Talk

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17 paź 2025, 21:15 UTC

Market Talk

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

Peer Comparison

Price change

Glaukos Corp Forecast

Price Target

By TipRanks

32.3% upside

12 Months Forecast

Average 115.33 USD  32.3%

High 165 USD

Low 86 USD

Based on 13 Wall Street analysts offering 12 month price targets forGlaukos Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

11

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

87.61 / 93Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

123 / 371 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
help-icon Live chat